buprenorphine vs glecaprevir/pibrentasvir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of buprenorphine and glecaprevir/pibrentasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
↑= increase; ↓= decrease; ↔ = no effect 7.4 Medication-Assisted Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required when used concomitantly with MAVYRET.
Subutex, Sublocade
Mavyret
Buprenorphine sublingual tablets help treat opioid dependence. It should be part of a full treatment plan with counseling and support.
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
This medicine treats opioid dependence. Opioid dependence means you feel like you need to take opioids. This medicine can help you manage withdrawal symptoms and reduce cravings.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Buprenorphine is a partial opioid agonist. This means it binds to the same receptors in the brain as opioids, but it does not activate them as strongly. This helps to reduce cravings and withdrawal symptoms without causing the same high as other opioids.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
- • Headache
- • Nausea
- • Vomiting
- • Sweating
- • Constipation
- • Headache
- • Feeling tired
- • Nausea
- Death 13,278
- Drug Dependence 12,452
- Overdose 10,911
- Toxicity To Various Agents 10,722
- Pain 8,157
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
Buprenorphine can be abused, like other opioids. Taking buprenorphine with benzodiazepines or other depressants can cause serious breathing problems, coma, or death. Keep this medicine out of the reach of children, as it can cause severe breathing problems and death. Using opioids for a long time during pregnancy can cause withdrawal symptoms in the newborn.
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
If you are pregnant or plan to become pregnant, talk to your doctor. Using this medicine during pregnancy can cause withdrawal symptoms in your baby after birth. Buprenorphine can pass into breast milk.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Also Compare, Nearby Drugs
Compare buprenorphine with
How to Read This buprenorphine vs glecaprevir/pibrentasvir Comparison
buprenorphine is classified in the Partial Opioid Agonist drug class, while glecaprevir/pibrentasvir sits within the NS3/4A/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, buprenorphine has 55,520 submissions while glecaprevir/pibrentasvir has 7,019. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these drugs do not significantly change how the other works or how they are processed by the body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for buprenorphine or glecaprevir/pibrentasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.